Molecular modeling study on the disassembly of dendrimers designed as potential antichagasic and antileishmanial prodrugs

Journal of Molecular Modeling

Volumn 18, Issue 5, 2012, Pages 2257-2269

  Giarolla, Jeanine ^a   Pasqualoto, Kerly F M ^a   Rando, Daniela G ^b   Zaim, Márcio H ^a   Ferreira, Elizabeth I ^a  

^a LAPEN   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chagas disease; Dendrimer disassembly; Dendrimeric Prodrugs; Leishmaniasis; Molecular modeling

Indexed keywords

3 HYDROXYFLAVONE; ANTILEISHMANIAL AGENT; ANTITRYPANOSOMAL AGENT; DENDRIMER; HYDROXYMETHYLNITROFURAZONE; INOSITOL; MALIC ACID; NITROFURAL; PRODRUG; QUERCETIN; UNCLASSIFIED DRUG;

ARTICLE; CHAGAS DISEASE; DRUG DESIGN; DRUG STRUCTURE; LEISHMANIASIS; MOLECULAR MODEL; PRIORITY JOURNAL;

DENDRIMERS; FLAVONOIDS; INOSITOL; MALATES; MOLECULAR DYNAMICS SIMULATION; NITROFURAZONE; PRODRUGS; QUERCETIN; STATIC ELECTRICITY; THERMODYNAMICS; TRYPANOCIDAL AGENTS;

EID: 84861227611     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-011-1244-8     Document Type: Article

References (40)

1. Coura JR, Dias JCP (2009) Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz 104:31-40
2. Coura JR, Viñas PA (2010) Chagas disease: a new worldwide challenge. Nature 465:S6-S7
3. Clayton J (2010) Chagas disease 101. Nature 465:S4-S5
4. Clayton J (2010) Chagas disease: pushing through the pipeline. Nature 465:S12-S15
5. Lindoso JAL, Lindoso AABP (2009) Neglected tropical disease in Brazil. Rev Inst Med Trop S Paulo 51:247-253
6. Neuber H (2008) Leishmaniasis. J Dtsch Dermatol Ges 6:754-765
7. Herwaldt BL (1991) Leishmaniasis. Lancet 354:1191-1199
8. Yardley V, Khan AA, Martin MB, Slifer TR, Araujo FG, Moreno SNJ, Docampo R, Croft SL, Oldfield E (2002) In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplama gondii. Antimicrob Agents Chemother 46:929-931 (Pubitemid 34157693)
9. Singh S, Sivakumar RJ (2004) Challenges and new discoveries in the treatment of leishmaniasis. Infect Chemother 10:307-315 (Pubitemid 40142819)
10. Santos DO, Coutinho CER, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, Bernardino A, Bourguignon SC, Corte-Real S, Pinho RT, Rodrigues CR, Castro HC (2008) Leishmaniasis treatment - a challenge that remains: a review. Parasitol Res 103:1-10
11. Chung MC, Güido RVC, Martinelli TF, Gonçalves MF, Polli MC, Botelho KCA, Varanda EA, Colli W, Miranda MTM, Ferreira EI (2003) Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone produg. Bioorg Med Chem 11:4779-4783 (Pubitemid 37230134)
12. Davies C, Cardoso RM, Negrette OS, Mora MC, Chung MC, Basombrío MA (2010) Hydroxymethylnitrofurazone is active in a murine model of Chagas disease. Antimicrob Agents Chemother 54:3584-3589
13. Güido RVC, Ferreira EI, Nassute JC, Varanda EA, Chung MC (2001) Diminuição da atividade mutagênica do pró- fármaco NFOH-121 em relação ao NF (nitrofurazona). Rev Cienc Farm 22:319-333 (Pubitemid 35033671)
14. Tasdemir D, Kaiser M, Brun R, Yardley V, Schmidt TJ, Tosun F, Ruedi P (2006) Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure-activity relationship, and quantitative structure-activity relationship studies. Antimicrob Agents Chemother 50:1352-1364
15. Kayser O, Kiderlen EAF, Croft ESL (2003) Natural products as antiparasitic drugs. Parasitol Res 90:55-62
16. Chung MC, Silva ATA, Castro LF, Guido RVC, Nassute JC, Ferreira EI (2005) Latenciação e formas avançadas no transporte de fármacos. Rev Bras Cienc Farm 41:155-179 (Pubitemid 41415074)
17. Chung MC, Ferreira EI, Santos JL, Giarolla J, Rando DG, Almeida AE, Bosquesi PL, Menegon RN, Blau L (2008) Prodrugs for the treatment of neglected diseases. Molecules 13:616-677
18. Svenson S (2009) Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 71:445-462
19. Aulenta F, Hayes W, Rannard S (2003) Dendrimers: a new class of nanoscopic containers and delivery devices. Eur Polym J 39:1741-1771
20. Uhrich K, Cannizzaro S, Langer R, Shakesheff K (1999) Polymeric systems for controlled drug release. Chem Rev 99:3181-3198 (Pubitemid 129583051)
21. Liu M, Fréchet JMJ (1999) Designing dendrimers for drug delivery. Pharm Sci Technol Today 2:393-401 (Pubitemid 29452933)
22. D'Emanuele A, Attwood D (2005) Dendrimer-drug interactions. Adv Drug Deliv Rev 57:2147-2162 (Pubitemid 41760432)
23. Najlah M, Freeman S, Attwood D, D'Emanuele A (2007) In vitro evaluation of endrimer prodrugs for oral drug delivery. Int J Pharm 336:183-190 (Pubitemid 46551566)
24. Giarolla J, Ferreira EI (2007) Patent 018070068714 (under analysis)
25. Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Fréchet JMJ, Dy EE, Szoka FC (2006) A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA 103:16649-16654 (Pubitemid 44737307)
26. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D (2004) The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Rel 95:447-453 (Pubitemid 38340495)
27. Giarolla J, Rando DG, Pasqualoto KFM, Zaim MH, Ferreira EI (2010) Molecular modeling as a promising tool to study dendrimer prodrugs delivery. J Mol Struct THEOCHEM 939:133-138
28. Hypercube Inc. (2002) HYPERCHEM, v.7.0 for Windows. Hypercube Inc., Gainesville
29. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2011) The Protein Data Bank. http://www.pdb.org
30. Caddick S, Muskett FW, Stoneman RG, Woolfson DN (2006) Synthetic ligands for apo-neocarzinostatin. J Am Chem Soc 128:4204-4205
31. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wvmann MP, Williams RL (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Molecular Cell 6:909-919
32. Race PR, Lovering AL, Green RM, Ossor A, White SA, Searle PF, Wrighton CJ, Hyde EI (2005) Structural and mechanistic studies of Escherichia coli nitroreductase with the antibiotic nitrofurazone. Reversed binding orientations in different redox states of the enzyme. J Biol Chem 280:13256-13264 (Pubitemid 40517209)
33. Doherty A (1997) MOLSIM: molecular mechanics and dynamics simulation software - user's guide, version 3.2. The Chem21 Group Inc., Lake Forest
34. Allinger NL (1977) Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J Am Soc 99:8127-8134
35. Dewar MJS, Healy EF, Holder AJ, Yuan YC (1990) Comments on a comparison of AM1 with the recently developed PM3 method. J Comput Chem 11:541-542
36. Tokarski JS, Hopfinger AJ (1997) Prediction of ligand-receptor binding thermodynamics by free energy force field. J Chem Inf Comput Sci 37:792-811
37. Forsythe KH, Hopfinger AJ (1973) The Influence of solvent on the secondary structures of poly(L-alanine) and poly(L-proline). Macromolecules 6:423-437
38. Gaussian Inc. (1995-2003) Gaussian 03W for Windows, v.6. Gaussian Inc., Pittsburgh
39. Accelrys Inc. (2001) ViewerLite 4.2. Accelrys Inc., San Diego
40. McNaught AD, Wilkinson A, IUPAC (1997) Compendium of chemical terminology, 2nd edn (the "Gold Book"). Blackwell, Oxford (on-line corrected version: http://goldbook.iupac. org; created by Nic M, Jirat J, Kosata B, updates compiled by Jenkins A, ISBN 0-9678550-9-8; doi:10.1351/goldbook, 2006)